FivepHusion

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Details:

Under the Agreement, Allarity will support FivepHusion’s future clinical development of Deflexifol (5-fluorouracil) for the treatment of solid tumors by using certain of Allarity’s drug-specific DRP® companion diagnostics, including its validated DRP®-5FU companion diagnostic.

Lead Product(s): Fluorouracil,Calcium Folinate,Oxaliplatin

Therapeutic Area: Oncology Product Name: Deflexifol

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Allarity Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 31, 2023

ASK
US

Upload
your Marketing & Sales content

FivepHusion

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health

Details:

The collaboration is for strategically and optimally progress development and commercialization of FivepHusion's enhanced chemotherapeutic formulation Deflexifol, an anti-cancer drug reformulation combining 5-fluorouracil and its biomodulator leucovorin, in global markets.

Lead Product(s): Fluorouracil,Calcium Folinate

Therapeutic Area: Oncology Product Name: Deflexifol

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Syneos Health

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 26, 2023

ASK
US

Upload
your Marketing & Sales content